PAPAVERINE HYDROCHLORIDE

Possibly Marketed Outside US

First approved in 1995

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H21NO4.ClH
Molecular Weight	375.846
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1

InChI

InChIKey=UOTMYNBWXDUBNX-UHFFFAOYSA-N

InChI=1S/C20H21NO4.ClH/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16;/h5-8,10-12H,9H2,1-4H3;1H

HIDE SMILES / InChI

Molecular Formula	C20H21NO4
Molecular Weight	339.385
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/cdi/papaverine.html | https://www.ncbi.nlm.nih.gov/pubmed/16780899 | https://www.ncbi.nlm.nih.gov/pubmed/16159054 | https://media.fepblue.org/-/media/pdfs/medical%20policies/10-15-14/pharma/5_06_19_papaverine_powder.pdf

An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. Papaverine is a vasodilating agent. Papaverine is used for the treating certain conditions that are accompanied by smooth muscle spasms (eg, blood vessel, urinary, gallbladder, or intestinal spasm). Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries. Papaverine is a potent, specific inhibitor of PDE10A. Papaverine for treatment of erectile dysfunction (ED) is excluded from coverage.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphodiesterase 10A 13 Target ID: CHEMBL4409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16780899 \| https://www.ncbi.nlm.nih.gov/pubmed/20447563 \| https://www.ncbi.nlm.nih.gov/pubmed/21705115	Inhibitor 8504	36.0 nM [IC50]
Human immunodeficiency virus 8 Target ID: CHEMBL613758 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2713167 \| https://www.ncbi.nlm.nih.gov/pubmed/7506701	Inhibitor 8504
Telomerase reverse transcriptase 10 Target ID: CHEMBL2916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25111025	Inhibitor 8504	60.0 µM [IC50]
HERG 99 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19034039	Inhibitor 8504	0.58 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Spasm of smooth muscle 5 Sources: https://www.drugs.com/cdi/papaverine.html	Primary		Approved 8583	Papaverine Approved Use Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic.

C_max

Value	Dose	Analyte	Population
54.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24217241/	3 mg single, intravascular dose: 3 mg route of administration: Intravascular experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
583 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
117 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
536 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
218 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1760 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
375 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1965 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
855 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1308 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
409 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1247 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
800 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PAPAVERINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg 3 times / day multiple, oral Higher than recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6340562/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6340562/	Disc. AE: Alkaline phosphatase increased, SGOT increased... AEs leading to discontinuation/dose reduction: Alkaline phosphatase increased (4%) SGOT increased (4%) Eosinophilia (4%) Sources: https://pubmed.ncbi.nlm.nih.gov/6340562/
15 g single, oral Overdose Dose: 15 g Route: oral Route: single Dose: 15 g Sources: https://pubmed.ncbi.nlm.nih.gov/7248034/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7248034/	Disc. AE: Consciousness decreased, Respiration abnormal... AEs leading to discontinuation/dose reduction: Consciousness decreased Respiration abnormal Metabolic acidosis Respiratory alkalosis Sinus tachycardia Hypokalemia (grade 2) Hyperglycemia (grade 1) Pyruvate increased Sources: https://pubmed.ncbi.nlm.nih.gov/7248034/
8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Sources: https://pubmed.ncbi.nlm.nih.gov/12811723/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12811723/	Disc. AE: Lactic acidosis, Hypokalemia... AEs leading to discontinuation/dose reduction: Lactic acidosis (grade 3) Hypokalemia Coma (grade 5) Convulsions (grade 3) Vomiting (grade 3) Respiratory alkalosis (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/12811723/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP1A2 2153 CYP2E1 1060 CYP2C19 2057 MRP4 290 OATP1B1 1079 MRP3 246 BSEP 550 OATP1B3 961 OCT1 620 MRP2 499	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	inconclusive [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTkyMjQifX0=	inconclusive [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	no [IC50 >10 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	no [IC50 >133 uM]
OCT1 656	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1Njg1IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	weak [Inhibition 100 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	yes [IC50 0.762 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTkyMjQifX0=	yes [IC50 1.9953 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	yes [IC50 12.5893 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	yes [IC50 23.13 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	yes [IC50 <10 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4MTIzIn19	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4MTIzIn19	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/4680#section=BioAssay-Results Page: 575 \| 580	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTkyMjQifX0=

PubMed

Title	Date	PubMed
A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression.	2015-05	25633564
Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.	2011-08-25	21777010
The modulation of protein kinase A and heat shock protein 70 is involved in the reversible increase of blood-brain tumor barrier permeability induced by papaverine.	2010-11-20	20728510
Cardiac arrest after intracisternal papaverine instillation during intracranial aneurysm surgery. Case report.	2010-10	19961315
Resolution of peripheral artery catheter-induced ischemic injury in infants -Two case reports-.	2010-08	20740220
Vascular smooth muscle contraction/relaxation of rat carotid artery is not altered by bone grafting substitutes in vitro.	2010-06	20039182
Antibodies against gonadotropin-releasing hormone (GnRH) and destruction of enteric neurons in 3 patients suffering from gastrointestinal dysfunction.	2010-05-20	20487533
New endovascular method for transvascular exit of arteries and veins: developed in simulator, in rat and in rabbit with full clinical integration.	2010-05-03	20454668
Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation.	2010-05	20447563
Micro computed tomography for vascular exploration.	2010-03-05	20298533
Intravascular ultrasound study and evidence of pathological coronary flow reserve in patients with isolated coronary artery aneurysms.	2010-03	20047052
Severe hypotension with intracisternal application of papaverine after clipping of an intracranial aneurysm.	2009-12	19604547
Intracisternal irrigation of papaverine leading to choroidal infarction.	2009-11	19901231
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.	2009-11	19661377
[Acute embolization into the veins in the splanchnic bed--an overview of current methods of diagnosis and therapies].	2008-11	19069681
Peyronie's reconstruction for maximum length and girth gain: geometrical principles.	2008	19081785
QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine.	1994	7511988
Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.	1991-06	2038782
Torsades de pointes after intracoronary papaverine.	1991-02	2044564
Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.	1991-01	1984099
A lethal complication of papaverine-induced priapism.	1991-01	1984077
[Priapism as a complication of the treatment of impotence by local injections of papaverine].	1990-09-01	2278150
Intracavernous papaverine and glaucoma.	1990-08-01	2366292
Determination of coronary flow reserve by digital angiography: validation of a practical method not requiring power injection or electrocardiographic gating.	1990-07	2358592
Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve.	1990-04	2334953
Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine.	1990-02	2299067
Intracavernous papaverine in the management of psychogenic impotence.	1990	2327828
Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine.	1989-12	2605630
[The intracavernosal administration of papaverine in the diagnosis and treatment of sexual disorders in men].	1989-10	2617964
Papaverine-induced chest pain due to coronary vascular steal: demonstration with angiographic and intracoronary flow velocity measurements.	1989-08	2750660
[Epilepsy and hypertensive crisis after intracavernous injection of metaraminol in the treatment of priapism secondary to a papaverine test].	1989-05-20	2524805
Inhibitory effect of papaverine on HIV replication in vitro.	1989-04	2713167
[Papaverine-induced priapism. Experiences with a new urologic emergency].	1989-02-10	2917481
Comparison of the anti-respiratory syncytial virus activity and toxicity of papaverine hydrochloride and pyrazofurin in vitro and in vivo.	1989-02	2653219
Papaverine-induced fibrosis of the corpus cavernosum.	1989-01	2908935
Serious ventricular dysrhythmias after intracoronary papaverine.	1988-12-01	2461650
[Therapy of erectile dysfunction using papaverine--2 1/2 years' experience].	1988-07-30	3175561
[Long-term experiences with autoinjection therapy of papaverine in erectile dysfunction].	1988-01	3363769
Papaverine-induced coma.	1988	3366170
Diagnosis of male impotence after intracavernous papaverine test.	1988	3215253
Pressor inhibition of angiotensin-induced ACTH secretion.	1987-11	2835134
[Intracavernous injection of papaverine hydrochloride for impotence in patients with spinal cord injury].	1987-07	3687629
Incompatibility of Hexabrix and papaverine in peripheral arteriography.	1987-03	3809473
Maintenance treatment of erectile impotence by cavernosal unstriated muscle relaxant injection.	1986-08	3640652
[Efficacy of intracisternal papaverine on symptomatic vasospasm].	1986-06	3762853
Papaverine-induced chronic liver disease.	1986-04	3949106
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies.	1985-09-01	4029887
Validation in dogs of a rapid digital angiographic technique to measure relative coronary blood flow during routine cardiac catheterization.	1985-01-01	3881002
Intraoperative assessment of aortoiliac stenosis: role of papaverine-induced hyperemia.	1984-12	6240483
Spasmolytic constituents of Cedrus deodara (Roxb.) Loud: pharmacological evaluation of himachalol.	1975-02	47907

Patents

Sample Use Guides

In Vivo Use Guide

Papaverine Hydrochloride may be administered intravenously or intramuscularly. The intravenous route is recommended when an immediate effect is desired, but the drug must be injected slowly over the course of 1 or 2 minutes to avoid uncomfortable or alarming side effects. Parenteral administration of papaverine hydrochloride in doses of 1 to 4 mL is repeated every 3 hours as indicated. In the treatment of cardiac extrasystoles, 2 doses may be given 10 minutes apart.

Route of Administration: Parenteral

In Vitro Use Guide

In bovine cauda epididymal and ejaculated spermatozoa, the major cAMP-PDE activity was papaverine-sensitive (44.5% and 57.5%, respectively, at 400 nm of papaverine).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:45:02 GMT 2025` Edited by `admin` on `Mon Mar 31 17:45:02 GMT 2025`
Record UNII	23473EC6BQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-35443

Preferred Name

English

PAPAVERINE HYDROCHLORIDE

Common Name

English

Papaverine hydrochloride [WHO-DD]

Common Name

English

PAPAVERINE HYDROCHLORIDE [MI]

Common Name

English

PAPAVERINE HYDROCHLORIDE [HSDB]

Common Name

English

6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride

Systematic Name

English

PAPAVERINE HCL

Common Name

English

PAPAVERINE HYDROCHLORIDE [WHO-IP]

Common Name

English

VASORIN

Common Name

English

ISOQUINOLINE, 1-((3,4-DIMETHOXYPHENYL)METHYL)-6,7-DIMETHOXY-, HYDROCHLORIDE

Systematic Name

English

PAPAVERINE HYDROCHLORIDE [USP-RS]

Common Name

English

PAPAVERINE HYDROCHLORIDE [MART.]

Common Name

English

ARTEGODAN

Common Name

English

CARDOVERINA

Common Name

English

PAPAVERINE HYDROCHLORIDE [VANDF]

Common Name

English

PAPAVERINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

PAPAVERINE HYDROCHLORIDE [JAN]

Common Name

English

PAPAVERINI HYDROCHLORIDUM [WHO-IP LATIN]

Common Name

English

PAPAVERINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29707